Group 1: Berteli / Automotive Parts - The company plans to acquire 50.9727% of Yubei Steering, enhancing its steering business capabilities. The acquisition involves purchasing shares from multiple stakeholders, with a valuation not exceeding 2.2 billion yuan [3] - Yubei Steering's main business includes the production and sales of automotive steering systems and components, with projected revenues of 3.03 billion yuan and 3.18 billion yuan for 2024 and 2025, respectively [3] - The company has strong development capabilities in mechanical and electronic brake products, aiming to innovate continuously in vehicle brake systems and provide comprehensive solutions [4] Group 2: Geely Automobile - Geely's total sales in February 2026 reached 206,000 units, showing a slight year-on-year increase of 0.6%, while the cumulative sales for January-February were 476,000 units, up 1.0% year-on-year [6][7] - The company is focusing on high-end product launches, with several new models set to debut in the first half of 2026, including the flagship SUV 8X and the hybrid SUV M7 [7][8] - Geely's export performance is strong, with February exports reaching 61,000 units, a year-on-year increase of 138.3%, and cumulative exports for January-February at 121,000 units, up 129.4% [8] Group 3: Great Wall Motors - Great Wall Motors sold 73,000 vehicles in February 2026, with a cumulative sales increase of 2.6% year-on-year for January-February [10][11] - The company aims to achieve a total sales target of 1.8 million vehicles for 2026, with 600,000 units expected to come from overseas markets [11][12] - The upcoming V9X model, a luxury six-seat SUV, is set to launch in the second quarter of 2026, featuring advanced technology and performance specifications [12] Group 4: Leap Motor - Leap Motor delivered 28,000 vehicles in February 2026, marking an 11.0% year-on-year increase, with a cumulative delivery of 60,000 units for January-February, up 19.2% [14][15] - The company plans to launch several new models in 2026, including the A10, which emphasizes intelligent features and long-range capabilities [15] - Leap Motor is initiating a new retail strategy to enhance customer experience and diversify sales channels [15] Group 5: Swine Breeding Industry - The swine breeding industry is facing intensified losses, with a potential restart of capacity reduction measures. The national breeding sow inventory decreased by 2.9% year-on-year as of December 2025 [17][18] - The industry is seeing increased concentration, with the top 20 swine breeding companies accounting for 36% of the market share, up 5 percentage points year-on-year [17] - The report suggests a left-side layout for the swine breeding sector, recommending leading companies such as Muyuan Foods and Wens Foodstuffs [18] Group 6: BeiGene / Chemical Pharmaceuticals - BeiGene reported a total revenue of $5.34 billion in 2025, a 40% year-on-year increase, with product revenue also growing by 40% [25][26] - The company expects to achieve revenue guidance of $6.2 to $6.4 billion for 2026, with significant contributions from its key products [25] - The rapid growth of its drug Zebrutinib, particularly in the U.S. market, is a key driver of revenue, with a global sales figure of $3.9 billion in 2025 [26][27]

Core Insights - The company reported 2025 revenue of $5.343 billion, a 40% year-over-year increase, with product revenue at $5.282 billion, also up 40% [1] - GAAP net profit reached $287 million, slightly below expectations due to a one-time equity investment impairment and non-recurring tax issues in Q4 2025; excluding these impacts, net profit is expected to meet projections [1] Revenue Growth - Zebutinib drove steady product revenue growth, with 2025 sales of $3.9 billion, a 49% increase year-over-year; quarterly sales were $790 million, $950 million, $1.04 billion, and $1.15 billion, with quarter-over-quarter changes of -4%, +20%, +10%, and +10% respectively [2] - Global sales of Tislelizumab reached $740 million in 2025, a 19% increase year-over-year; GAAP net profit of $287 million marked the first quarterly profit [2] Future Guidance - The company maintains strong growth guidance for 2026, projecting full-year revenue between $6.2 billion and $6.4 billion, a 16-20% increase; GAAP gross margin is expected to remain high at around 80% [2] - GAAP operating expenses are projected to be between $4.7 billion and $4.9 billion, a year-over-year increase of 11-16%; GAAP operating profit is expected to be between $700 million and $800 million [2] Upcoming Catalysts - The company anticipates several key catalysts in 2026, including potential approval for Sotorasib in R/R MCL in 1H26, and accelerated approval for BTK CDAC in R/R CLL based on Phase II data in 2H26 [3] - Phase III trials for CDK4 in 1L breast cancer are set to start in 1H26, with Phase I data expected to be disclosed in the same period; B7-H4 ADC Phase III trials will also commence within 12 months, with Phase I data to be released in 1H26 [3] Profit Forecast and Valuation - Considering domestic healthcare price adjustments and cost control, the company has lowered its 2026 revenue forecast by 2.7% but maintains a profit forecast of $610 million, introducing a 2027 profit forecast of $870 million [4] - The company maintains an outperform rating, with target prices based on DCF model set at 320 CNY, 250 HKD, and 420 USD, representing upside potentials of 36.2%, 40.1%, and 41.4% respectively [4]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company reported a sales figure of $1.1 billion for Zebutinib in Q4, representing a year-over-year increase of 38% and a quarter-over-quarter increase of 10%. Sales in the U.S. reached $845 million, with a year-over-year increase of 37% and a quarter-over-quarter increase of 14% [1] - The gross margin improved by 4.7 percentage points year-over-year to 90.5%, while the general and administrative expense ratio decreased by 7.7 percentage points year-over-year. The non-GAAP net profit surged to $225 million year-over-year [1] - The company guides for revenue between $6.2 billion to $6.4 billion by 2026, with GAAP operating expenses projected at $4.7 billion to $4.9 billion, and a gross margin expected to remain high in the 80% range. The non-GAAP net profit is forecasted to be between $1.4 billion to $1.5 billion [1] Business Focus Areas - The company is focusing on four major areas: 1) Chronic Lymphocytic Leukemia (CLL): Sotoclisib is expected to be launched in Europe and the U.S. within the year, with BTKCDAC anticipated to submit for approval in the second half of 2026. The fixed-cycle therapy of Zebutinib and Sotoclisib has recently initiated a Phase III trial [2] 2) Other Hematological Malignancies: Leveraging Zebutinib, Sotoclisib, and CD19/CD20 targeted tri-antibodies, bispecific antibodies, and cell therapies to expand into other lymphomas, multiple myeloma (MM), and acute myeloid leukemia (AML) indications [2] 3) Solid Tumors: Focused on breast cancer, lung cancer, and gastrointestinal tumors. Recent success in PD-1 and HER2 bispecific antibody combined with chemotherapy in first-line HER2+ gastric cancer is expected to expand overseas application scenarios. CDK4, B7H4ADC, and GPC3/4-1BB bispecific antibodies are either in or will initiate registration studies within the next 12 months [2] 4) Inflammation/Immunology: Early data for BTKCDAC and IRAK4CDAC is expected to be read out in 2026 [2]

Core Viewpoint - BeiGene has achieved a historic turnaround in 2025, reporting total revenue of 38.205 billion yuan, a year-on-year increase of 40.4%, and a net profit of 1.422 billion yuan, marking the first annual profit since its establishment 16 years ago [1][2]. Financial Performance - The significant revenue growth is primarily driven by product sales, which reached 37.770 billion yuan, accounting for 98.9% of total revenue [1]. - The core product, BTK inhibitor Zebutini (brand name: Baiyueze), generated global sales of 28.067 billion yuan, up 48.8% year-on-year [1]. - The anti-PD-1 drug Tislelizumab (brand name: Baizean) achieved global sales of 5.297 billion yuan, a year-on-year increase of 18.6% [1]. - The sales from licensed products from Amgen amounted to 3.471 billion yuan, reflecting a 33.6% increase [1]. Market Reaction - Despite the positive earnings report, BeiGene's stock prices fell significantly across multiple markets, with a 9.16% drop in Hong Kong stocks and a 5.65% decline in A-shares on the first trading day after the announcement [2][3]. - The market capitalization has decreased to below 280 billion HKD, indicating investor concerns despite the reported profitability [2]. Profitability Concerns - The fourth-quarter net profit is estimated at 284 million yuan, a significant decline from 689 million yuan in the third quarter, raising concerns about quarterly volatility [3]. - The revenue forecast for 2026 is projected to be between 43.6 billion and 45 billion yuan, indicating a growth rate of only 14.12% to 17.79%, which is a substantial decrease compared to the 40.4% growth in 2025 [3]. Dependency Risks - BeiGene's profitability is heavily reliant on its core product Baiyueze, which contributes over 70% of total revenue [4]. - The sales growth of Baiyueze in the U.S. market has slowed significantly, with a 45.5% increase in 2025 compared to a 107.5% increase in 2024 [4]. - The company faces risks from over-reliance on a single product and market, as 72% of Baiyueze's revenue comes from the U.S. market [4]. Competitive Landscape - The competitive environment is intensifying, with AbbVie's ibrutinib being included in the U.S. price negotiation list, potentially leading to price reductions starting January 1, 2026 [4]. - The expiration of patents for first-generation BTK inhibitors in the U.S. and Europe is expected to increase competition from generic drugs [4]. Future Growth Potential - BeiGene's second major product, anti-PD-1 drug Tislelizumab, is also facing challenges in a highly competitive market [6]. - The company has received approval for its self-developed drug Sotokluda (Baiyueda) in China and has submitted a marketing application in the EU, which could become a new core product [7][8]. - The company aims to create the next successful product following Baiyueze, as future growth is critical for maintaining investor confidence [8].

Market Overview - The pharmaceutical and biotechnology index fell by 0.34% last week, underperforming the Shanghai Composite Index by 2.32 percentage points [1][2] - The A-share innovative drug sector saw a slight increase of 0.43%, while the Hong Kong healthcare index and innovative drug ETF dropped significantly by 4.95% and 4.05%, respectively [1][2] Company Performance - BeiGene, a leading innovative drug company, experienced a significant decline in stock price despite reporting strong financial results, with total revenue expected to reach 38.205 billion yuan in 2025, a year-on-year increase of 40.4%, and a net profit of 1.422 billion yuan, marking a 1400% increase [2][3] - Following the earnings announcement, BeiGene's stock price dropped by 9.16% at one point, closing at 194.40 HKD per share, with a total market capitalization falling below 300 billion HKD [2] Market Dynamics - The market is currently focused on performance realization and growth expectations, with increased risk aversion among investors in the Hong Kong market [2][3] - There is a notable shift in the pricing logic for innovative drug companies, moving from a focus on pipeline reserves to a comprehensive evaluation of R&D capabilities, commercialization abilities, and compliance [3] New IPOs - Huge Dental Limited has submitted its application to the Hong Kong Stock Exchange for a listing, aiming to capitalize on its position as a leading supplier of dental materials in China [4][5] - The company has faced challenges in its previous attempts to list on A-shares and has now shifted its focus to the Hong Kong market, marking its third attempt to go public [4][5] Clinical Research Updates - From February 23 to March 1, the National Medical Products Administration disclosed 123 new clinical trial registrations, with 38 of these being innovative drugs in Phase II or higher [7] - Notable clinical trials include studies on treatments for moderate to severe ulcerative colitis and advanced gynecological malignancies, among others [8] Drug Approvals - Five innovative drugs received approval during the week, including a dual-target inhibitor for primary myelofibrosis and a KRAS G12C inhibitor for advanced non-small cell lung cancer [15][16] - The approval of these drugs highlights significant advancements in treatment options for conditions with high unmet medical needs [15][16] Research Insights - A recent report identified 100 new drug targets for 2025, with cancer-related targets making up 50% of the list, indicating a strong focus on oncology in drug development [12] - Over half of these targets were discovered by Chinese research teams, showcasing the country's growing influence in innovative drug research [12]

Core Viewpoint - Despite achieving its first annual profit, BeiGene's stock price fell significantly after the earnings report, reflecting market concerns about growth quality and pipeline execution pace [1][14]. Financial Performance - In 2025, BeiGene reported a total revenue of 38.205 billion yuan, a year-on-year increase of 40.4%, with product revenue reaching 37.77 billion yuan, accounting for nearly 99% of total revenue [2][15]. - The company achieved a net profit attributable to shareholders of 1.422 billion yuan, marking a turnaround from a loss of 4.978 billion yuan in the previous year [2][16]. - The adjusted net profit was 1.381 billion yuan, a significant improvement from a loss of 5.379 billion yuan the previous year [2][16]. Product Performance - The star product, Bruton’s tyrosine kinase (BTK) inhibitor, achieved global sales of 28.067 billion yuan in 2025, a 48.8% increase, representing 73.8% of the company's product revenue [3][17]. - Sales in the U.S. reached 20.206 billion yuan, up 45.5%, while European sales surged 66.4% to 4.265 billion yuan, and Chinese sales grew 33.1% to 2.472 billion yuan [4][17]. Cost and Efficiency - The gross margin for products under GAAP increased to 87.3%, up from 84.3% the previous year, indicating improved cost control [5][18]. - Research and development expenses were 21.46 billion yuan, a 9.88% increase, while sales and management expenses were 20.81 billion yuan, up 13.65%, both growing slower than revenue [6][20]. Cash Flow and Assets - Free cash flow for 2025 was 9.42 billion yuan, a significant recovery from a negative cash flow of 6.33 billion yuan the previous year [7][20]. - Total assets reached 57.423 billion yuan, a 34.1% increase from the beginning of the year, driven by steady cash inflows from operations [7][20]. Market Concerns - The company provided a revenue guidance of 6.2 to 6.4 billion USD for 2026, indicating a slowdown to approximately 20% growth compared to 40% in 2025, raising concerns about future growth potential [8][21]. - The market is worried about the ability of the pipeline to deliver new growth, as the first wave of core products enters a mature growth phase [9][21]. Pipeline and Future Growth - The second-tier products are experiencing slower execution, with the BCL2 inhibitor expected to receive regulatory decisions in 2026, but large-scale commercialization will take time [10][22]. - Early-stage pipeline products are unlikely to generate significant revenue in the near term, leading to concerns about the sustainability of growth in the next few years [11][23].

Core Viewpoint - Company BeiGene is expected to achieve total revenue of $5.3 billion in 2025, representing a year-on-year increase of 40%, and a GAAP net profit of $287 million, marking a turnaround to profitability [1] Financial Performance - The performance aligns with expectations, as the early research pipeline enters a harvest phase [1] - For 2026, the company provides guidance of total revenue between $6.2 billion and $6.4 billion, GAAP operating expenses of $4.7 billion to $4.9 billion, and a gross margin in the high 80% range [1] - GAAP operating profit is projected to be between $700 million and $800 million, while non-GAAP operating profit is expected to be between $1.4 billion and $1.5 billion [1] Product and Pipeline Development - The company's core products are experiencing rapid growth, and the research pipeline is anticipated to see significant catalysts [1] - Due to increased R&D investment, net profit forecasts for 2026 and 2027 have been adjusted to $685 million and $1.08 billion, respectively, down from previous estimates of $795 million and $1.22 billion [1] - A new net profit forecast for 2028 has been introduced at $1.897 billion [1] Market Position and Strategy - The company maintains a solid position as a leader in the domestic biopharma sector, with significant achievements in global expansion [1] - Both commercialization and research are approaching critical inflection points, leading to a maintained "Buy" rating [1]

Core Viewpoint - The report from CMB International highlights the strong sales performance of BeiGene (06160.HK) in Q4, with a significant year-over-year increase in revenue and profitability, indicating a positive outlook for the company and maintaining a "Buy" rating. Financial Performance - BeiGene's sales of Zebrutinib reached $1.1 billion in Q4, representing a year-over-year increase of 38% and a quarter-over-quarter increase of 10% [1] - Sales in the U.S. amounted to $845 million, with a year-over-year increase of 37% and a quarter-over-quarter increase of 14% [1] - The gross margin improved by 4.7 percentage points year-over-year to 90.5% [1] - General and administrative expenses decreased by 7.7 percentage points year-over-year [1] - Non-GAAP net profit surged to $225 million year-over-year [1] Future Guidance - The company projects revenue between $6.2 billion and $6.4 billion for 2026 [1] - GAAP operating expenses are expected to be between $4.7 billion and $4.9 billion [1] - Gross margin is anticipated to remain high in the 80% range [1] - Non-GAAP net profit is forecasted to be between $1.4 billion and $1.5 billion [1] Market Position and Analyst Ratings - BeiGene's market capitalization is approximately HKD 274.15 billion, ranking first in the biopharmaceutical II industry [1] - The majority of investment banks maintain a "Buy" rating for the stock, with two firms issuing buy ratings in the last 90 days [1] - The average target price over the last 90 days is HKD 223.43 [1] - Guotai Junan Securities recently issued a "Buy" rating for BeiGene [1]

Group 1 - The core viewpoint of the report indicates that BeiGene's (06160) sales of Zebrutinib reached $1.1 billion in Q4 last year, representing a year-on-year increase of 38% and a quarter-on-quarter increase of 10% [1] - The sales in the U.S. amounted to $845 million, with a year-on-year increase of 37% and a quarter-on-quarter increase of 14% [1] - The gross margin improved by 4.7 percentage points year-on-year to 90.5%, while the general and administrative expense ratio decreased by 7.7 percentage points year-on-year [1] Group 2 - The company is focusing on four major areas: 1) Chronic Lymphocytic Leukemia (CLL) with potential launches of Sotigalimab in Europe and the U.S. within the year, and BTK CDAC expected to submit for approval in 2H26 [2] - 2) Other hematological malignancies leveraging Zebrutinib and Sotigalimab along with CD19/CD20 targeted therapies to expand into other lymphomas, multiple myeloma (MM), and acute myeloid leukemia (AML) [2] - 3) Solid tumors with a focus on breast cancer, lung cancer, and gastrointestinal tumors, including recent success in a PD-1 + HER2 dual antibody + chemotherapy regimen for 1L HER2+ gastric cancer [2] - 4) Inflammation/Immunology with early data from BTK CDAC and IRAK4 CDAC expected to be read out in 2026 [2]

Group 1 - The core viewpoint of the report indicates that BeiGene's (06160) sales of Zebrutinib reached $1.1 billion in Q4 last year, representing a year-on-year increase of 38% and a quarter-on-quarter increase of 10% [1] - U.S. sales accounted for $845 million, with a year-on-year increase of 37% and a quarter-on-quarter increase of 14% [1] - The gross margin improved by 4.7 percentage points year-on-year to 90.5%, while the general and administrative expense ratio decreased by 7.7 percentage points [1] Group 2 - The company is focusing on four major areas: 1) Chronic Lymphocytic Leukemia (CLL) with potential launches of Sotigalimab in Europe and the U.S. within the year, and plans to submit a BTK CDAC application in 2H26 [2] - 2) Other hematological malignancies leveraging Zebrutinib and Sotigalimab, along with CD19/CD20 targeted therapies to expand into other lymphomas, multiple myeloma (MM), and acute myeloid leukemia (AML) [2] - 3) Solid tumors with a focus on breast cancer, lung cancer, and gastrointestinal tumors, having recently achieved success with a PD-1 + HER2 dual antibody + chemotherapy regimen in 1L HER2+ gastric cancer [2] - 4) Inflammation/Immunology with early data expected from BTK CDAC and IRAK4 CDAC in 2026 [2] Group 3 - The company has guided for revenues of $6.2 billion to $6.4 billion by 2026, with GAAP operating expenses projected at $4.7 billion to $4.9 billion, and a gross margin expected to remain high in the 80% range [1] - Non-GAAP net profit is anticipated to be between $1.4 billion and $1.5 billion [1] - The company maintains a "Buy" rating [1]